Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer

Diagnostic Pathology

Feilun Cui¹  Liansheng Zhang¹  Zhen Qiu¹  Jianpeng Hu¹ 

[1] Department of Urology, People’s Hospital Affiliated of Jiangsu University, Zhenjiang 212002, Jiangsu, China

关键词: Environmental risk factor;    Nucleotide polymorphisms;    Prostate cancer;   

Others  :  801900
DOI  :  10.1186/1746-1596-9-84

 received in 2013-08-20, accepted in 2014-03-15,  发布年份 2014

【 摘 要 】

Objective

To investigate the relationship and interaction of the single nucleotide polymorphisms (SNPs) of KLK3 and VDR and environmental factors with the predisposition to prostate cancer within Chinese population.

Methods

The comparison between 108 patients and 242 healthy people was carried out by using the TaqMan/MGB Probe Technology to determine the genotypes of KLK3(rs2735839 is located between KLK2 and KLK3) and VDR (rs731236 is located exon 9). Univariate and multivariate logistic regression model were used to assess the connection of genetic polymorphisms and environmental risk factors with PCa by collecting demographic information, as well as BMI, consumption of cigarettes, alcohol, and tea, exercise, and other environmental risk factors.

Results

The appearing frequencies of AA, AG, and GG genotypes at the SNPs rs2735839 (A/G) for KLK3 were 13.89%, 62.96% and 23.15% in PCa and 37.19%, 44.63%, 18.18% in control, respectively; these two groups are statistically different (P = 0.00). While the appearing frequencies of TT, TC, and CC genotypes at the SNPs rs731236 (T/C) for VDR were 88.89%, 9, 26%, 1.85% and 90.50%, 9.10%, 0.40% in control, respectively, with no significant statistical difference between the two group. The study confirmed decreasing risk in tea drinkers (OR = 0.58, 95% CI = 0.35-0.96).

Conclusions

Our studies indicate that environmental factor-tea drinking is associated with the development of PCa. The habit of drinking tea is a protective factor against PCa. The SNPs rs2735839 for KLK3 is strongly related to the development of PCa, while the SNPs rs731236 for VDR is not.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9759981571058803 webcite.

【 授权许可】

   
2014 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Ye D, Li CL: Review and prospects of prostate cancer incidence trends. The Chinese Cancer 2007, 17:177-180.
• [3]Sonoda T, Nagata Y, Mori M, Miyanaga N, Takashima N, Okumura K, Goto K, Naito S, Fujimoto K, Hirao Y: A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 2004, 95(3):238-42.
• [4]Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J: A common variant associated with prostate cancer in European and African populations. Nat Genet 2006, 38:652-658.
• [5]Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G: Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007, 99:1836-44.
• [6]Chu LW, Reichardt JK, Hsing AW: Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008, 15:261-270.
• [7]Lawrence MG, Lai J, Clements JA: Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010, 31:407-446.
• [8]Paliouras M, Borgono C, Diamandis EP: Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007, 249:61-79.
• [9]Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996, 56:4108-4110.
• [10]Inglesb SA, Ross RK, Yu MC, Irvine RA, LaPera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (Bethesda) 1997, 89:166-170.
• [11]Berndt SI, Dodson JL, Huang WY, Nicodemus KK: A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006, 175:1613-1623.
• [12]Dabir PD, Ottosen P, Høyer S, Hamilton-Dutoit S: Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol 2012, 7:81. BioMed Central Full Text
• [13]Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R: Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol 2012, 7:68. BioMed Central Full Text
• [14]Lichtenstein P, Holm NV, Verkasalo PK, Liadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer: analysis of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
• [15]Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J: Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40:316-321.
• [16]Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A: Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40:310-315.
• [17]Xu JF, Isaacs SD, Sun JL, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS: Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008, 14:5819-5824.
• [18]Zheng SL, Hsing AW, Sun J, Sun J, Chu LW, Yu K, Li G, Gao ZR, Kim ST, Isaacs WB, Shen MC: Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese Men. Prostate 2010, 70(4):425-432.
• [19]Kader AK, Sun JL, Isaacs SD, Wiley KE, Yan GF, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC: Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009, 69:1195-1205.
• [20]Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungeström M, Wingren S: Association of breast cancer progression with a vitamin D receptor gene polymorphism, South—East Sweden Breast Cancer Group. Cancer Res 1999, 59(10):2332-2334.
• [21]Ye WZ, Reis AF, Velho G: Identification of a novel Tru9 I polymorphism in the human vitamin D receptor gene. J Hum Genet 2000, 45(1):56-57.
• [22]Alagarasu K, Selvaraj P, Swaminathan S, Narendran G: Narayanan PR.5′ regulatory and 3′ untranslated region polymorphisms of vitamin D receptor gene in south Indian HIV and HIV-TB patients. J Clin Immunol 2009, 29:196-204.
• [23]Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C: The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European popularion. J Hum Genet 2002, 47:413-418.
• [24]Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, Vutuc C, Micksche M: Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002, 5l:30-34.
• [25]Saleem M, Adhami VM, Siddiqui IA, Asim M, Mukhtar H: Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer 2003, 47:13-23.
• [26]Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, JPHC Study Group: Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008, 167:71-77.
• [27]Park OJ, Surh YJ: Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett 2004, 150:43-56.
• [28]Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J, Jing B: Association of Micro- RNA-126 expression with clinicopathological features and the risk of bio chemical recurrence in prostate cancer patients undergoing radical prostatectomy. Diagn Pathol 2013, 8:208. BioMed Central Full Text
• [29]Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H: Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 2012, 7:127. BioMed Central Full Text